RUNX2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P06839(RUNX2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P06839(RUNX2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The RUNX2 antibody is a crucial tool in biomedical research for studying the Runt-related transcription factor 2 (RUNX2), a master regulator of osteoblast differentiation and skeletal development. RUNX2. also known as core-binding factor subunit alpha-1 (CBFA1), plays a pivotal role in bone formation, chondrocyte maturation, and tooth development by controlling the expression of osteogenic genes like osteocalcin (BGLAP) and collagen type I alpha 1 (COL1A1). It contains a conserved Runt domain for DNA binding and protein interactions. Dysregulation of RUNX2 is implicated in skeletal disorders (e.g., cleidocranial dysplasia), metastatic bone diseases, and cancers, particularly osteosarcoma and breast/prostate cancer with bone metastasis.

Researchers use RUNX2 antibodies to detect and quantify RUNX2 protein levels in various applications, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). These antibodies help investigate RUNX2's nuclear localization, expression patterns during osteogenesis, and interactions with co-regulators like CBFβ. Commercial RUNX2 antibodies are typically raised against specific epitopes, such as the N-terminal or C-terminal regions, and validated across species (human, mouse, rat). Recent studies also utilize RUNX2 antibodies to explore its non-skeletal roles in vascular calcification, immune regulation, and epithelial-mesenchymal transition. Validation via knockout controls or siRNA knockdown remains essential due to potential cross-reactivity with other RUNX family members (RUNX1. RUNX3).